Article
Chemistry, Medicinal
Anastasiia S. Boiko, Irina A. Mednova, Elena G. Kornetova, Valeria I. Gerasimova, Alexander N. Kornetov, Anton J. M. Loonen, Nikolay A. Bokhan, Svetlana A. Ivanova
Summary: This study compared the changes in cytokine levels in schizophrenia patients receiving atypical antipsychotics with or without metabolic syndrome. The results showed that treatment with atypical antipsychotics had different effects on inflammatory cytokine levels depending on the presence of MetS. Patients with MetS experienced increased levels of certain cytokines, while those without MetS had decreased levels of other cytokines after treatment.
Review
Medicine, General & Internal
Wiktor Drozdz, Michal Wicinski, Anna Maria Szota, Monika Szambelan, Izabela Radajewska, Igor Poplawski, Pawel Wojciechowski
Summary: This review examines the efficacy of combining neuroleptic and non-antipsychotic treatment in individuals with schizophrenia. The results suggest that a combination of antipsychotic medication with aspirin, simvastatin, N-acetylcysteine, or pioglitazone can significantly reduce both negative and positive symptoms of schizophrenia.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Psychiatry
Dragana Bugarski-Kirola, Rene Nunez, Ramzey Odetalla, I-Yuan Liu, Mary Ellen Turner
Summary: This study investigated the effect of adding pimavanserin as an adjunctive treatment on QT interval prolongation in patients with schizophrenia. The results showed that there was no evidence of QT prolongation exceeding 500 ms when pimavanserin was added to the treatment.
FRONTIERS IN PSYCHIATRY
(2022)
Review
Psychiatry
Leslie Citrome, Jan Volavka
Summary: This text discusses the evaluation of the anti-hostility effects of atypical antipsychotic agents, highlighting the research on clozapine and other atypical antipsychotics in terms of their independent impact on hostility. It also points out some limitations of the studies conducted in this area.
HARVARD REVIEW OF PSYCHIATRY
(2021)
Article
Clinical Neurology
Anna Dietrich-Muszalska, Joanna Kolodziejczyk-Czepas, Pawel Nowak
Summary: The study shows that patients with schizophrenia have higher levels of oxidative stress compared to healthy subjects, but a 4-week treatment with atypical antipsychotics can reduce lipid peroxidation and increase total plasma antioxidant activity.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2021)
Article
Psychiatry
Xinyu Fang, Chunying Gao, Weifeng Wu, Xiuxiu Hu, Miaomiao Shao, Chou Zhou, Renliang Cai, Jin Fang, Yi Li, Yue Xu, Xiangrong Zhang
Summary: This study explored the relationship between weight gain in schizophrenia patients with atypical antipsychotic treatment and gut microbiome. The results showed that there were no significant differences in alpha diversity between normal-weight and overweight schizophrenia patients treated with atypical antipsychotics. However, the beta diversity analysis revealed distinct clustering patterns for overweight and normal-weight patients. The composition of the gut microbiome also differed between the two groups. Function prediction identified several pathways that were significantly different between groups. Correlation analysis indicated associations between specific bacteria and BMI. Overall, these findings suggest that perturbations in the gut microbiome composition and functional pathways may contribute to weight gain in schizophrenia patients treated with atypical antipsychotics.
PSYCHIATRY RESEARCH
(2023)
Article
Medicine, Research & Experimental
Akitoyo Hishimoto, Norio Yasui-Furukori, Daisuke Sekine, Miyuki Matsukawa, Sakiko Yamada
Summary: This study compared the time to treatment discontinuation between patients with schizophrenia prescribed brexpiprazole (BRX) and those prescribed other atypical antipsychotics (OAA) using health insurance claims data. The results showed that patients in the BRX group were less likely to discontinue treatment and had higher treatment continuation rates compared to the OAA group.
ADVANCES IN THERAPY
(2022)
Article
Chemistry, Medicinal
Marek Krzystanek, Anna Warchala, Beata Tredzbor, Ewa Martyniak, Katarzyna Skalacka, Artur Palasz
Summary: Sexual dysfunctions in patients with schizophrenia are often severe and may be related to antipsychotic medication side effects or the illness itself. This study suggests that amantadine could be a potential treatment for improving sexual functioning in these patients.
Article
Biochemistry & Molecular Biology
Banny Silva Barbosa Correia, Joao Victor Nani, Raniery Waladares Ricardo, Danijela Stanisic, Tassia Brena Barroso Carneiro Costa, Mirian A. F. Hayashi, Ljubica Tasic
Summary: This study evaluated the effects of antipsychotic drugs on blood serum lipids in an SCZ animal model and normal control rats, revealing similar lipid alterations to those seen in SCZ patients. The use of psychostimulants in normal rats resulted in decreased ω-3 fatty acids, similar to the first episode of psychosis in SCZ. CLZ was found to reverse lipid metabolism changes in SHR.
Review
Chemistry, Analytical
Vasanti Suvarna, Adishri Raut
Summary: Atypical antipsychotics have become popular for treating various psychopathological diseases in the past decade due to their better clinical profile and therapeutic benefits. However, their usage can lead to peripheral side effects and metabolic diseases, impacting patients' quality of life. Therefore, developing analytical methods to accurately identify and quantify these drugs from different formulations and biological samples is crucial in clinical and forensic settings.
CURRENT ANALYTICAL CHEMISTRY
(2023)
Article
Clinical Neurology
Matthew Harlin, Craig Chepke, Frank Larsen, Karimah S. Bell Lynum, Sanjeda R. Chumki, Heather Fitzgerald, Pedro Such, Jessica Madera-McDonough, Murat Yildirim, Moeen Panni, Stephen R. Saklad
Summary: Aripiprazole 2-month ready-to-use 960 mg and Aripiprazole lauroxil 1064 mg are both long-acting injectable formulations used for the treatment of schizophrenia. Comparing the drug concentrations, both formulations maintain therapeutic levels over the 2-month dosing interval.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2023)
Article
Behavioral Sciences
Gary Remington, Margaret K. Hahn, Sri Mahavir Agarwal, Araba Chintoh, Ofer Agid
Summary: The introduction of chlorpromazine led to schizophrenia being repositioned as a biological illness. The evolution of antipsychotics, from 'typical' to 'atypical', and drug development that aligns with the illness' heterogeneity and complexity are explored. It may be time to reconsider the notion of developing drugs that specifically treat 'schizophrenia'.
BEHAVIOURAL BRAIN RESEARCH
(2021)
Article
Psychiatry
Yuta Kawakita, Masahiro Takeshima, Tomonari Komatsu, Aya Imanishi, Dai Fujiwara, Yu Itoh, Kazuo Mishima
Summary: This study retrospectively compared the incidence of appendicitis in patients with schizophrenia with and without a history of clozapine exposure, finding a relationship between clozapine exposure and appendicitis onset.
Review
Medicine, General & Internal
Bartosz Dawidowski, Adrianna Gorniak, Piotr Podwalski, Zofia Lebiecka, Blazej Misiak, Jerzy Samochowiec
Summary: Schizophrenia may be associated with immune dysfunction, with alterations in cytokine levels, childhood trauma, and disturbances in the gut microbiome potentially influencing its pathomechanism and clinical presentation. Different subtypes of schizophrenia, such as deficit schizophrenia, show variations in peripheral cytokine levels. The narrative review provides a comprehensive presentation of the evidence, utilizing a holistic approach to understand the complex relationships involved.
JOURNAL OF CLINICAL MEDICINE
(2021)
Biographical-Item
Psychology, Clinical
Mary V. Seeman
Summary: Philip Seeman's discovery of the dopamine D2 receptor's isolation is an example of how a small step can lead to a major shift in our understanding of the etiology of schizophrenia.
PSYCHOLOGICAL MEDICINE
(2022)